Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Galenica Offers For Relypsa, But Other Suitors May Emerge

Executive Summary

Allergan backs out of deal with Adamis for an EpiPen competitor just two months after signing the licensing deal, but before an up-front payment due date kicks in. AbCellera to team with MassBiologics to discover antibodies against drug-resistant Klebsiella infections.

Advertisement

Related Content

Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
Galderma Steps Into Biologics With Chugai Eczema Antibody
Chronos' Deal With Shire Is 'Just The Start' Of Its Acquisitive New Strategy
Jounce Gets $261m To Start, Milestone Fees Up To $2.3bn In Celgene Deal
Juno Picks Up A2a Receptor Via Redox Acquisition
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Keeping Track: FDA Approval Activity Heats Up With Ocaliva, Zinbryta And More
AstraZeneca's ZS-9 Timeline Hit By FDA Complete Response Letter
Deal Watch: GSK Accelerates TCR Collaboration With Adaptimmune
Relypsa’s Potassium-Lowering Drug Clears FDA, But Dosing Warning Could Impact Use

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096952

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel